CO2019007186A2 - Moduladores de ror gamma (rorγ) - Google Patents

Moduladores de ror gamma (rorγ)

Info

Publication number
CO2019007186A2
CO2019007186A2 CONC2019/0007186A CO2019007186A CO2019007186A2 CO 2019007186 A2 CO2019007186 A2 CO 2019007186A2 CO 2019007186 A CO2019007186 A CO 2019007186A CO 2019007186 A2 CO2019007186 A2 CO 2019007186A2
Authority
CO
Colombia
Prior art keywords
rorγ
formula
ror gamma
gamma modulators
modulators
Prior art date
Application number
CONC2019/0007186A
Other languages
English (en)
Inventor
Joseph Maria Gerardus Barbara Cals
David Machnik
Sander Bernardus Nabuurs
Jean-François Sabuco
Original Assignee
Sanofi Sa
Lead Pharma Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Lead Pharma Holding Bv filed Critical Sanofi Sa
Publication of CO2019007186A2 publication Critical patent/CO2019007186A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

La presente solicitud se refiere a los compuestos de acuerdo con la (Fórmula IA) o (Fórmula IB): (Fórmula IA) (Fórmula IB) o una sal farmacéuticamente aceptable de los mismos. Los compuestos se pueden utilizar como inhibidores de RORγ y son útiles para el tratamiento de las enfermedades mediadas por RORγ.
CONC2019/0007186A 2016-12-05 2019-07-03 Moduladores de ror gamma (rorγ) CO2019007186A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16202175 2016-12-05
PCT/EP2017/081489 WO2018104288A1 (en) 2016-12-05 2017-12-05 ROR gamma (RORy) modulators

Publications (1)

Publication Number Publication Date
CO2019007186A2 true CO2019007186A2 (es) 2019-08-20

Family

ID=57482312

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0007186A CO2019007186A2 (es) 2016-12-05 2019-07-03 Moduladores de ror gamma (rorγ)

Country Status (34)

Country Link
US (3) US10196350B2 (es)
EP (1) EP3548016B1 (es)
JP (1) JP6955563B2 (es)
KR (1) KR102554776B1 (es)
CN (1) CN110352054B (es)
AR (1) AR110481A1 (es)
AU (1) AU2017373593B2 (es)
BR (1) BR112019010461A2 (es)
CA (1) CA3045946A1 (es)
CL (1) CL2019001406A1 (es)
CO (1) CO2019007186A2 (es)
CR (1) CR20190321A (es)
DK (1) DK3548016T3 (es)
DO (1) DOP2019000119A (es)
EA (1) EA201991373A1 (es)
EC (1) ECSP19047767A (es)
ES (1) ES2830759T3 (es)
HU (1) HUE052470T2 (es)
IL (1) IL267045B (es)
LT (1) LT3548016T (es)
MA (1) MA46965B1 (es)
MX (1) MX2019006517A (es)
MY (1) MY194174A (es)
NZ (1) NZ755105A (es)
PE (1) PE20191545A1 (es)
PH (1) PH12019501231A1 (es)
PL (1) PL3548016T3 (es)
PT (1) PT3548016T (es)
RS (1) RS60964B1 (es)
TW (1) TWI705958B (es)
UA (1) UA123751C2 (es)
UY (1) UY37507A (es)
WO (1) WO2018104288A1 (es)
ZA (1) ZA201902288B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101009A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
TWI705958B (zh) 2016-12-05 2020-10-01 荷蘭商領導醫藥控股責任有限公司 ＲＯＲγ調節子
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2572334A1 (en) 2004-07-01 2006-01-19 New York University Compositions and methods for modulation of ror.gamma.t
WO2011115892A1 (en) 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2013029338A1 (en) 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
US9394315B2 (en) 2012-05-08 2016-07-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
WO2013171729A2 (en) * 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator
US9359315B2 (en) 2013-09-10 2016-06-07 Arrien Pharmaceuticals Llc Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
MX368721B (es) 2013-12-05 2019-10-14 Lead Pharma Holding Bv Moduladores de ror gamma (rory).
TW201605797A (zh) 2013-12-10 2016-02-16 葛蘭馬克製藥公司 作為ror伽馬調節物的雙環雜芳基化合物
ES2663498T3 (es) 2013-12-19 2018-04-13 Merck Patent Gmbh Tetrahidro-tetrazolo[1,5-a]pirazinas como inhibidores de ROR-gamma
WO2015101928A1 (en) 2013-12-31 2015-07-09 Aurigene Discovery Technologies Limited Fused thiophene and thiazole derivatives as ror gamma modulators
CA2938311C (en) 2014-02-03 2023-03-07 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ror-gamma
AU2015237788B2 (en) 2014-03-27 2021-03-11 Piramal Enterprises Limited ROR-gamma modulators and uses thereof
CN107266454B (zh) 2014-04-14 2019-08-09 勃林格殷格翰国际有限公司 作为RORγ调节剂的化合物
PL3294713T4 (pl) 2015-05-15 2021-07-26 Aurigene Discovery Technologies Limited Podstawione związki tetrahydrochinolinonowe jako modulatory ror gamma
EP3101009A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101006A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101008A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101007A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101005A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
UA122148C2 (uk) 2015-08-03 2020-09-25 Гленмарк Фармасьютікалс С.А. Сполуки як модулятори ror-гамма
WO2017213137A1 (ja) 2016-06-09 2017-12-14 アグロカネショウ株式会社 新規化合物およびこれを有効成分とする農園芸用薬剤
TWI705958B (zh) 2016-12-05 2020-10-01 荷蘭商領導醫藥控股責任有限公司 ＲＯＲγ調節子
JP2019026575A (ja) 2017-07-27 2019-02-21 アグロカネショウ株式会社 新規化合物およびこれを有効成分とする農園芸用殺菌剤

Also Published As

Publication number Publication date
US11299456B2 (en) 2022-04-12
IL267045B (en) 2021-07-29
CN110352054B (zh) 2022-11-01
PT3548016T (pt) 2020-10-08
DOP2019000119A (es) 2019-09-30
PL3548016T3 (pl) 2021-02-08
EP3548016B1 (en) 2020-09-02
CR20190321A (es) 2019-09-11
BR112019010461A2 (pt) 2019-09-10
US10196350B2 (en) 2019-02-05
WO2018104288A1 (en) 2018-06-14
CN110352054A (zh) 2019-10-18
LT3548016T (lt) 2021-01-11
EA201991373A1 (ru) 2019-11-29
EP3548016A1 (en) 2019-10-09
AR110481A1 (es) 2019-04-03
CA3045946A1 (en) 2018-06-14
US20200190028A1 (en) 2020-06-18
MA46965B1 (fr) 2020-12-31
ECSP19047767A (es) 2019-08-30
KR20190096365A (ko) 2019-08-19
DK3548016T3 (da) 2020-11-16
US20180162808A1 (en) 2018-06-14
ES2830759T3 (es) 2021-06-04
UA123751C2 (uk) 2021-05-26
TWI705958B (zh) 2020-10-01
NZ755105A (en) 2023-01-27
PH12019501231A1 (en) 2019-09-23
US20190119204A1 (en) 2019-04-25
IL267045A (en) 2019-07-31
ZA201902288B (en) 2020-10-28
MX2019006517A (es) 2019-08-22
RS60964B1 (sr) 2020-11-30
HUE052470T2 (hu) 2022-02-28
JP6955563B2 (ja) 2021-10-27
KR102554776B1 (ko) 2023-07-11
JP2020500886A (ja) 2020-01-16
CL2019001406A1 (es) 2019-10-18
MY194174A (en) 2022-11-17
AU2017373593B2 (en) 2022-04-07
AU2017373593A1 (en) 2019-07-25
PE20191545A1 (es) 2019-10-24
UY37507A (es) 2018-06-29
TW201835038A (zh) 2018-10-01

Similar Documents

Publication Publication Date Title
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
CO2018002060A2 (es) Compuestos farmacéuticos
CL2020001218A1 (es) Compuestos útiles para inhibir a cdk7.
UY36708A (es) MODULADORES DE ROR GAMMA (RORy)
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
SV2016005192A (es) Composiciones y métodos para modular los receptores x farnesoides
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
CL2016000698A1 (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
CL2016001364A1 (es) Moduladores de ror gamma (rory)
UY36077A (es) Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienen
NI201800071A (es) Compuestos de isoindol
AR103680A1 (es) Inhibidores selectivos de bace1
MX2017015740A (es) Moduladores de ror gamma (ror?).
UY36709A (es) Moduladores de ror gamma (ror¿)
UY36747A (es) Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen
MX2017015739A (es) Moduladores de ror gamma (ror?).
DOP2017000034A (es) Compuestos de imidazopiridazina
CO2019007186A2 (es) Moduladores de ror gamma (rorγ)
CU20170153A7 (es) Compuestos tricíclicos útiles como inhibidores de la fosfodiesterasa
CR20160527A (es) Derivados de carboxamida
UY36228A (es) Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CL2016001843A1 (es) Uso de una composición que comprende a) un compuesto de fórmula (ia) definida o una sal del mismo y b) un portador o excipiente farmacéuticamente aceptable para preparar un medicamento útil para tratar una afección alérgica en un mamífero.
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano